Last updated: 2026-10-13 22:01:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
uniQure N.V. (QURE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $21.27, with a market capitalization of $1.57B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $8.73 to $71.50. This page covers its latest market performance, valuation, price trends and company information.
$1.57B | |
$21.66 | |
$82.49 | |
$3.73 | |
$21.84 | |
2.27M | |
1.99M | |
-- | |
$71.50 | |
$8.73 | |
-- | |
-- |
uniQure N.V. (QURE) is trading at $21.20 in after-hours trading as of 2026-10-13 21:57:00, down 2.95% ($0.64) from the regular-session close of $21.84.
After-hours trading shows how investors are pricing QURE after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, uniQure N.V. (QURE) moved from $23.46 to $21.27, representing a decline of 9.36% ($2.20).
The stock traded between $20.87 and $23.84 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2.12 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 20.0%
QURE is currently trading at $21.27, placing it 20.0% of the way from its 52-week low of $8.73 to its 52-week high of $71.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 221 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of uniQure N.V. (QURE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.